and overall survival probabilities (p¼0.12). At multivariable Cox regression analysis in the postPSM cohort, age (p¼0.048), pT stage >2 (p¼0.003) and nodal metastasis (p<0.001) were independent predictors of DFS (Table 2) . CONCLUSIONS: RARC with intracorporeal UD and ORC provide comparable mid term oncologic outcomes. United Kingdom INTRODUCTION AND OBJECTIVES: There is currently lack of sufficient data on the long-term oncological outcomes after robotassisted radical cystectomy. The aim of this study is to compare the long-term oncological outcomes of robot-assisted with open radical cystectomy.
INTRODUCTION AND OBJECTIVES: Over the past decade, robotic-assisted radical cystectomy (RARC) has slowly gained acceptance in the urology community. However, the benefits of RARC over ORC remain controversial. Our objective was to conduct a comparative effectiveness analysis between RARC and ORC using data from the National Cancer Data Base (NCDB).
METHODS: Within the NCDB, we identified patients with nonmetastatic muscle-invasive bladder cancer (BC) who underwent RC between 2010 and 2013. Patients were stratified according to surgical approach: ORC or RARC. Oncologic endpoints measured included the presence of positive surgical margins, the performance of a pelvic Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1279 lymph node dissection, and number of lymph nodes removed. Perioperative outcomes measured included length of stay (LOS), 30-day and 90-day postoperative mortality rates, as well as 30-day readmission following surgery. To minimize selection bias, observed differences in baseline characteristics between patients who received RARC vs. ORC were controlled for using a weighted propensity score analysis. Using weighted data, all endpoints were assessed using propensity-adjusted logistic regression analyses. RESULTS: Of 9,561 patients who underwent RC, 2,048 (21.4%) and 7,513 (78.6%) underwent RARC and ORC, respectively. The use of RARC has increased over time, from 16.7% in 2010 to 25.3% in 2013. With regard to oncologic outcomes, RARC was associated with similar positive surgical margins (9.4% vs. 10.7% OR:0.86, 95%CI 0.72-1.04, p¼0.12), higher rates of lymphadenectomy (96.4% vs. 92.0%, OR: 2.31, 95%CI 1.68-3.19, p<0.001), higher median lymph node count (17 vs. 12, p<0.001) and higher rates of lymph node count above the median (56.8% vs. 40.4%, OR: 1.95, 95%CI 1.56-2.43, p<0.001). With regard to postoperative outcomes, receipt of RARC was associated with a shorter median LOS (7 vs. 8, p<0.001), lower rates of pLOS (45.1% vs. 54.8%, OR: 0.68, 95%CI 0.58-0.79, p<0.001), lower 30-day (1.5% vs. 2.8%, OR: 0.49, 95%CI 0.29-0.82, p¼0.007) and 90day postoperative mortality (5.0% vs. 6.8%, OR: 0.72, 95%CI 0.54-0.95, p¼0.023).
CONCLUSIONS: Our large contemporary study shows the increased adoption of RARC between 2010 and 2013, with currently more than 1 out of 4 patients undergoing RARC. RARC was associated with higher LN counts, shorter LOS and lower postoperative mortality. 3) and 0.9 (IQR 0.5, 2.1) years respectively (p¼0.042). Patients with PC had higher pathologic tumor and nodal stage than those with other recurrences and no recurrences (p<0.0001). Pathologic factors associated with PC include lymphovascular invasion (29.5% vs 16.7%, p¼0.0002) and positive tumor margin (5.4% vs 2.9%, p¼0.0093). Patients with PC experience worse overall and cancer specific survival than other types of recurrence (Figure) .
Source of
CONCLUSIONS: PC occurred in almost 4% of our patients undergoing open RC. Worsening pathologic stage was associated with PC. Cancer death in patients with PC was almost universal at 5 years. Further analysis will be needed to determine risk factors for developing PC following RC.
Source of Funding: none
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ENHANCED RECOVERY AFTER RADICAL CYSTECTOMY REDUCES COST AND LENGTH OF STAY: THE JOHNS HOPKINS EXPERIENCE.
Alice Semerjian*, Niv Milbar, Max Kates, Michael Gorin, Heather Chalfin, Cary Stimson, William Yang, Steven Frank, Deb Hobson, Lindsay Robertson, Ken Lee, Michael Johnson, Phillip Pierorazio, Trinity Bivalacqua, Baltimore, MD INTRODUCTION AND OBJECTIVES: Many centers have adapted Enhanced Recovery after Surgery (ERAS) pathways to decrease hospital length of stay (LOS) and peri-operative complications. We report the Johns Hopkins ERAS experience, specifically evaluating complication rate, LOS, 30-and 90-day readmissions, and for the first time in an ERAS cohort, cost.
METHODS: ERAS protocol (Table 1) was implemented for radical cystectomy (RC) patients in November 2015. Outcomes. readmissions and cost were compared to a matched group of 54 RC patients from an 8-month period prior to the use of ERAS. Patients were excluded if indication was not for bladder cancer or if they underwent adjunct procedures. RESULTS: 58 consecutive ERAS patients were compared to 54 pre-ERAS patients ( Table 2) . Cost of index hospitalization was $30,450 in the ERAS group and $35,411 in the pre-ERAS group; readmission LOS and costs were comparable between groups. Median LOS was 5 days for the ERAS group and 8.5 days for the pre-ERAS group (p¼<0.001). The pre-ERAS group had a significantly increased use of nasogastric tube (30% vs. 13.8%) and parenteral nutrition (20.4% vs. 6.9%). A trend towards increased complications occurring during index hospitalization in the pre-ERAS group was observed, although not reaching statistical significance. The ERAS group experienced a slightly higher rate of 30-day readmission, though two were for ostomy appliance issues. The most common reason for readmission was infection in both groups; there was a higher rate of GI related readmissions in the ERAS group (Figure 1) . CONCLUSIONS: Implementation of the ERAS protocol at our center resulted in significantly reduced length of hospital stay and decreased cost, with comparable rates of complication and readmission.
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